Boehringer’s HER2-mutated lung cancer drug shows sustained benefit for 14 months
After treatment with zongertinib, there was a median DoR of 14.1 months and median PFS of 12.4 months.
Therapy Area
Kura doses first subjects in trial of ziftomenib for advanced GIST
New data from J&J’s bladder cancer drug-device trial strengthens support for NDA
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trial
MSD reports outcomes from Keytruda combination trial for head and neck cancer
CERo announces SCRI as main site for trial of CER-1236 to treat AML
Renibus completes enrolment in RBT-1 trial to reduce post-cardiac surgery risk
